Johnson & Johnson Stock Is Always a Buy (If You Hold Long Enough)

Before you go, we thought you'd like these...
Before you go close icon

It's hard to argue that Johnson & Johnson stock is not a buy. Ever.

To prove my point, I looked at the multi-year chart and picked out some of the peaks. Even if you purchased near the yearly top, you're still sitting on a better return than if you had purchased an S&P 500 ETF.

Date

Johnson & Johnson Dividend-Adjusted Return

S&P 500 Dividend-Adjusted Return

June 27, 2012

34.1%

23.7%

June 8, 2011

40.6%

31.6%

April 9, 2010

49.3%

44.2%

Aug. 8, 2008

43.6%

38.8%

Oct. 20, 2006

56.6%

35.7%

Source: S&P Capital IQ.


Of course, Johnson & Johnson stock is sometimes a better buy than at other times. If you purchased near the yearly lows, you're sitting on an even better returns, trouncing the S&P500.

Date

Johnson & Johnson Dividend-Adjusted Return

S&P 500 Dividend-Adjusted Return

June 1, 2012

45.1%

29.2%

March 18, 2011

60.1%

32.3%

July 23, 2010

67.2%

55.4%

Source: S&P Capital IQ.

Run-up helped
The assumption that you'll be OK buying almost anytime works only if you hold on to Johnson & Johnson stock for long enough. I ran similar calculations looking at the returns through the end of last year, before Johnson & Johnson stock went on its monster run. The results weren't nearly as pretty.

Date

Johnson & Johnson Dividend Adjusted Return Through Dec. 31, 2012

S&P 500 Dividend-Adjusted Return Through Dec. 31, 2012

June 27, 2012

6.8%

8.3%

June 8, 2011

11.9%

15.2%

April 9, 2010

18.8%

26.2%

Aug. 8, 2008

14.3%

21.5%

Oct. 20, 2006

24.7%

18.8%

Source: S&P Capital IQ.

Apart from for the longest holding period -- the exception that proves the rule -- the S&P 500 topped the returns for Johnson & Johnson.

Looking forward
I think the recent run-up is justified, given how pessimistic investors have been over the last few years as Johnson & Johnson dealt with manufacturing issues and recalls. But I wouldn't be surprised if were near a yearly high, given how much Johnson & Johnson stock has increased over the first half of the year.

Fortunately, there are a few upcoming events that could help Johnson & Johnson stock increase in value, or at the very least help prop it up.

Second-quarter earnings are scheduled to be released on July 16. Investors should keep their eyes on Johnson & Johnson's recently launched diabetes drug Invokana. If Johnson & Johnson can persuade doctors to give it a try, there's potential for the drug to compete with Merck's top-selling oral medication Januvia. Taking just a portion of Januvia's multibillion-dollar market would give Johnson & Johnson stock a nice boost.

Investors should also watch Johnson & Johnson's hepatitis C drug Incivo that the health-care giant sells abroad for Vertex Pharmaceuticals . Even though it has to ship some of the profits to Vertex, Incivo is a moneymaker because doctors in Europe haven't started cutting back on prescribing the drug while they wait for next-generation hepatitis C drugs as they have in the U.S., where it's called Incivek.

Johnson & Johnson has one of those in the works, too. Toward the end of the year, look for a Food and Drug Administration approval of Johnson & Johnson's hepatitis C drug simeprevir, which will go up against Gilead Sciences' sofosbuvir, which will be approved around the same time. Data from the combinations of simeprevir with its partners' hepatitis C drugs will help investors gauge how well Johnson & Johnson can compete with the all-oral cocktail that Gilead is developing.

If you're on the lookout for high-yielding stocks outside of the health care sector, The Motley Fool's special free report "Secure Your Future With 9 Rock-Solid Dividend Stocks" outlines the Fool's favorite dependable dividend-paying stocks. Grab your free copy today by clicking here.

The article Johnson & Johnson Stock Is Always a Buy (If You Hold Long Enough) originally appeared on Fool.com.

Fool contributor Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences, Johnson & Johnson, and Vertex Pharmaceuticals and owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners